Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

LRRK2 antibody (AA 931-962)

LRRK2 Reactivity: Human WB, IHC (p) Host: Rabbit Polyclonal RB7199 unconjugated
Catalog No. ABIN1882109
  • Target See all LRRK2 Antibodies
    LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))
    Binding Specificity
    • 5
    • 4
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 931-962
    Reactivity
    • 18
    • 8
    • 1
    Human
    Host
    • 15
    • 3
    Rabbit
    Clonality
    • 14
    • 4
    Polyclonal
    Conjugate
    • 15
    • 1
    • 1
    • 1
    This LRRK2 antibody is un-conjugated
    Application
    • 12
    • 9
    • 7
    • 4
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
    Purification
    This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
    Immunogen
    This PARK8(LRRK2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 931-962 amino acids from human PARK8(LRRK2).
    Clone
    RB7199
    Isotype
    Ig Fraction
  • Application Notes
    WB: 1:1000. WB: 1:1000. IHC-P: 1:50~100
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
    Preservative
    Sodium azide
    Precaution of Use
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    4 °C,-20 °C
    Expiry Date
    6 months
  • Biskup, Moore, Rea, Lorenz-Deperieux, Coombes, Dawson, Dawson, West: "Dynamic and redundant regulation of LRRK2 and LRRK1 expression." in: BMC neuroscience, Vol. 8, pp. 102, (2008) (PubMed).

    Shen: "Protein kinases linked to the pathogenesis of Parkinson's disease." in: Neuron, Vol. 44, Issue 4, pp. 575-7, (2004) (PubMed).

    Wszolek, Pfeiffer, Tsuboi, Uitti, McComb, Stoessl, Strongosky, Zimprich, Müller-Myhsok, Farrer, Gasser, Calne, Dickson: "Autosomal dominant parkinsonism associated with variable synuclein and tau pathology." in: Neurology, Vol. 62, Issue 9, pp. 1619-22, (2004) (PubMed).

    Zimprich, Biskup, Leitner, Lichtner, Farrer, Lincoln, Kachergus, Hulihan, Uitti, Calne, Stoessl, Pfeiffer, Patenge, Carbajal, Vieregge, Asmus, Müller-Myhsok, Dickson, Meitinger, Strom, Wszolek, Gasser: "Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology." in: Neuron, Vol. 44, Issue 4, pp. 601-7, (2004) (PubMed).

  • Target
    LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))
    Alternative Name
    PARK8 (LRRK2) (LRRK2 Products)
    Synonyms
    LRRK2 antibody, AURA17 antibody, DARDARIN antibody, PARK8 antibody, RIPK7 antibody, ROCO2 antibody, 4921513O20Rik antibody, 9330188B09Rik antibody, AW561911 antibody, D630001M17Rik antibody, Gm927 antibody, cI-46 antibody, leucine-rich repeat kinase 2 antibody, leucine rich repeat kinase 2 antibody, lrrk2 antibody, LRRK2 antibody, Lrrk2 antibody
    Background
    Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. LRRK2 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.
    Molecular Weight
    286103
    NCBI Accession
    NP_940980
    UniProt
    Q5S007
    Pathways
    Regulation of G-Protein Coupled Receptor Protein Signaling, Skeletal Muscle Fiber Development
You are here:
Support